Medicinal chemistry in drug discovery in big pharma: past, present and future

被引:58
|
作者
Campbell, Ian B. [1 ]
Macdonald, Simon J. F. [1 ]
Procopiou, Panayiotis A. [1 ]
机构
[1] GlaxoSmithKline Med Res Ctr, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England
关键词
MOLECULAR COMPLEXITY; CANDIDATES; DESIGN; INDUSTRY; TARGETS; PROTEIN; SOLUBILITY; COMPANIES; LIGANDS; RULE;
D O I
10.1016/j.drudis.2017.10.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The changes in synthetic and medicinal chemistry and related drug discovery science as practiced in big pharma over the past few decades are described. These have been predominantly driven by wider changes in society namely the computer, internet and globalisation. Thoughts about the future of medicinal chemistry are also discussed including sharing the risks and costs of drug discovery and the future of outsourcing. The continuing impact of access to substantial computing power and big data, the use of algorithms in data analysis and drug design are also presented. The next generation of medicinal chemists will communicate in ways that reflect social media and the results of constantly being connected to each other and data.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 50 条